How to Get Evenity (Romosozumab) in Massachusetts

What Is Romosozumab and Why Does It Matter for Massachusetts Patients?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab has a dual mechanism: it increases bone formation while simultaneously reducing bone resorption. No other osteoporosis drug does both at once. The FDA approved Evenity in April 2019 for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors, or patients who have failed or are intolerant to other osteoporosis therapies.

In the ARCH trial (N=4,093), romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months. The FRAME trial (N=7,180) demonstrated a 73% reduction in new vertebral fractures versus placebo at 12 months. These are among the largest fracture-reduction signals in the osteoporosis literature.

Massachusetts has an aging population with approximately 1.2 million residents over 65 as of 2024 Census estimates. Osteoporosis affects roughly 10 million Americans, with another 44 million showing low bone density according to the National Osteoporosis Foundation and CDC data. For Bay State residents with severe disease, accessing romosozumab requires navigating prescribing, insurance authorization, and specialty pharmacy logistics. This guide covers each step.

Who Can Prescribe Evenity in Massachusetts?

Any licensed prescriber with authority to prescribe controlled and non-controlled medications in Massachusetts can write a romosozumab prescription. That includes physicians (MD/DO), nurse practitioners (NPs), and physician assistants (PAs). Massachusetts granted NPs full practice authority effective January 2021, meaning NPs can evaluate, diagnose, and prescribe independently without a collaborative physician agreement. PAs in Massachusetts still require a supervisory arrangement with a physician, but may prescribe romosozumab within their scope.

Rheumatologists, endocrinologists, and orthopedic specialists prescribe Evenity most frequently. Primary care physicians and geriatricians also initiate it, particularly in community settings where specialist wait times can stretch beyond three months. The prescriber must be comfortable interpreting DXA scans, FRAX scores, and metabolic bone labs, and should have a plan for post-romosozumab antiresorptive sequencing.

Telehealth is a viable path. Massachusetts permits telehealth prescribing for non-controlled medications without requiring an initial in-person visit, following the state's permanent telehealth parity law enacted in 2021. A board-certified endocrinologist or rheumatologist licensed in Massachusetts can evaluate imaging, review labs, and prescribe Evenity through a video visit. The injection itself will need to happen in a clinic or at home with proper training.

What Labs and Imaging Are Required Before Starting Evenity?

Before prescribing romosozumab, clinicians order a standard metabolic bone workup. Skipping these labs risks missed contraindications and prior authorization denials.

Required baseline labs:

• Serum calcium (corrected for albumin) to rule out hypocalcemia, which romosozumab can worsen
• 25-hydroxyvitamin D level; most guidelines target 30 ng/mL or above before starting any anabolic agent
• Comprehensive metabolic panel including creatinine and eGFR
• Serum phosphorus and magnesium
• Intact PTH to exclude primary hyperparathyroidism
• Bone turnover markers: P1NP (formation) and CTX (resorption) are useful for monitoring response

Required imaging:

• DXA scan within the past 24 months showing a T-score of -2.5 or below at the spine, femoral neck, or total hip, or evidence of osteopenia with a qualifying FRAX score or prior fragility fracture
• Lateral vertebral assessment (VFA) or lateral spine X-ray to identify existing vertebral fractures, which strengthen the prior authorization case

The Endocrine Society's 2020 guidelines recommend that patients with very high fracture risk (defined as recent fractures, T-scores below -3.0, or elevated FRAX probability above 30% for major osteoporotic fracture) be started on anabolic therapy first rather than bisphosphonates. This recommendation directly supports the use of romosozumab as initial treatment in appropriate patients.

Vitamin D deficiency must be corrected before the first dose. The standard repletion protocol is ergocalciferol 50,000 IU weekly for 8 to 12 weeks, followed by daily cholecalciferol 2,000 to 4,000 IU for maintenance, per Endocrine Society vitamin D guidelines.

Cardiovascular Screening: The Black Box Warning

Evenity carries an FDA black box warning for cardiovascular risk. The ARCH trial found a higher rate of major adverse cardiovascular events (MACE) with romosozumab versus alendronate: 2.5% vs 1.9% at the end of the open-label period [1]. The signal was driven primarily by myocardial infarction and stroke.

The prescribing label states: do not initiate romosozumab in patients who have had a myocardial infarction or stroke within the preceding year. The FDA labeling language goes further, advising clinicians to "consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors." This is not optional screening. It is a labeled contraindication.

Before prescribing, Massachusetts clinicians should document:

• Cardiovascular history review (MI, stroke, TIA, peripheral vascular disease)
• Blood pressure measurement
• Lipid panel within the past 12 months
• Assessment of 10-year ASCVD risk score

Patients with a history of MI or stroke in the prior 12 months should not receive romosozumab. For patients with elevated cardiovascular risk but no recent events, the prescriber must weigh fracture risk against MACE risk. That risk-benefit discussion should be documented in the chart, both for clinical quality and for prior authorization support.

How Prior Authorization Works for Evenity in Massachusetts

Massachusetts Medicaid (MassHealth) covers Evenity with prior authorization for severe osteoporosis. Most commercial insurers in the state, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim, Tufts Health Plan, and Fallon Health, also cover it with PA. The approval criteria are similar across payers but not identical.

Typical PA requirements include:

• Confirmed diagnosis of osteoporosis (ICD-10 M80.x or M81.x)
• DXA scan showing T-score of -2.5 or below, or documented fragility fracture
• Documentation that the patient is at high fracture risk (prior fracture, FRAX score, multiple risk factors)
• Trial and failure of, intolerance to, or contraindication to at least one oral bisphosphonate (alendronate, risedronate, or ibandronate). Some payers require a 12-month bisphosphonate trial; others accept documented intolerance after shorter exposure.
• Cardiovascular clearance documentation confirming no MI or stroke in the prior 12 months
• Lab results confirming corrected calcium is normal and vitamin D has been repleted

Processing timeline: MassHealth typically responds to PA requests within 48 to 72 hours for standard requests, and within 24 hours for urgent requests. Commercial payers vary, but most respond within 5 to 10 business days. If denied, Massachusetts patients have the right to an external appeal through the state's Office of Patient Protection. Amgen's Evenity Access Program and the Amgen Safety Net Foundation may provide assistance for uninsured or underinsured patients, with eligibility typically based on household income at or below 400% of the federal poverty level.

A common denial reason is insufficient documentation of bisphosphonate failure. Prescribers should submit clinic notes explicitly stating the bisphosphonate name, duration of use, reason for discontinuation (GI intolerance, esophageal stricture, atypical femoral fracture risk, inadequate BMD response), and supporting lab or imaging data.

Where to Fill an Evenity Prescription in Massachusetts

Evenity is a specialty medication. It will not be stocked at a neighborhood retail pharmacy. Patients fill their prescriptions through one of three channels.

Specialty pharmacies: Most insurers require patients to use a designated specialty pharmacy. CVS Specialty, Accredo (Express Scripts), and OptumRx are the most common in Massachusetts. These pharmacies handle cold-chain shipping (romosozumab requires refrigeration at 2°C to 8°C), coordinate with the prescriber on PA, and can ship directly to the patient or the administering clinic.

Buy-and-bill through the prescriber's office: Many rheumatology and endocrinology practices in Massachusetts use a buy-and-bill model, purchasing the drug through a distributor (such as McKesson or AmerisourceBergen), administering it in the office, and billing the patient's insurance under the medical benefit (J-code J3111). This route avoids specialty pharmacy logistics and ensures the patient receives their injection at the same visit.

503A compounding pharmacies: Massachusetts licenses 503A compounding pharmacies that may dispense romosozumab for individual patient prescriptions. These pharmacies compound or dispense under a patient-specific prescription and are regulated by the Massachusetts Board of Registration in Pharmacy. For a biologic like romosozumab, 503A pharmacies would dispense the commercially manufactured product rather than compound it, as biologics cannot be compounded in the traditional sense.

Most patients will receive their injection in a clinical setting. Each monthly visit takes about 15 to 30 minutes: two subcutaneous injections in the abdomen, thigh, or upper arm, administered sequentially. Some practices offer self-injection training after the first two to three supervised doses, though this is less common with romosozumab than with denosumab due to the dual-syringe administration.

Telehealth Pathways for Evenity in Massachusetts

Massachusetts has among the strongest telehealth protections in the country. The 2021 telehealth parity law (Chapter 260 of the Acts of 2020) requires insurers to cover telehealth services at the same reimbursement rate as in-person visits. There is no in-person visit requirement before initiating a telehealth relationship for non-controlled substances.

A practical telehealth workflow for Evenity in Massachusetts looks like this:

1. Initial telehealth consultation with a licensed Massachusetts prescriber (endocrinologist, rheumatologist, or experienced PCP). The patient uploads or shares DXA results, lab work, and relevant imaging.
2. Lab review and cardiovascular screening. If labs are outdated, the prescriber orders new panels through a local lab (Quest, Labcorp, or hospital-affiliated labs throughout Massachusetts).
3. Prescription and PA submission. The prescriber writes the Evenity prescription, initiates prior authorization, and coordinates with the specialty pharmacy.
4. In-person injection. While the prescription and evaluation can happen via telehealth, the injection itself requires a visit to a clinic, infusion center, or provider office. Some patients arrange administration through visiting nurse services or home health agencies licensed in Massachusetts.

For patients in western Massachusetts or Cape Cod, where specialist density is lower, telehealth eliminates a significant barrier to care. A patient in Pittsfield can consult with a bone specialist at Mass General Brigham or Beth Israel Deaconess without a four-hour round trip.

What Happens After 12 Months of Romosozumab?

Romosozumab is a time-limited therapy. After 12 monthly doses, bone formation markers return toward baseline, and the anabolic window closes. Without sequential antiresorptive therapy, the bone density gains reverse within 12 to 24 months.

The ARCH trial protocol transitioned patients from romosozumab to alendronate 70 mg weekly. In practice, Massachusetts clinicians sequence with either:

• Denosumab (Prolia) 60 mg subcutaneously every 6 months, which is the most common follow-on in specialty practice. Denosumab preserves and extends romosozumab's BMD gains, with data from the FRAME extension showing continued improvement at the spine through 36 months [2].
• Zoledronic acid (Reclast) 5 mg IV once yearly, preferred for patients who want fewer injections or who may have difficulty with denosumab's strict dosing schedule and the rebound vertebral fracture risk if denosumab is discontinued.
• Oral bisphosphonates (alendronate or risedronate), used when injectable options are not preferred or not covered.

The sequencing decision should be made before or during the romosozumab treatment course, not at month 12. Dr. Felicia Cosman, Professor of Clinical Medicine at Columbia University, has stated: "The biggest mistake in anabolic therapy is failing to plan the antiresorptive transition. Gains from romosozumab can be lost within a year without follow-on treatment." The treatment plan should include a specific drug, dose, and start date for the transition agent, documented in the medical record.

Cost, Copay Assistance, and Financial Navigation

Evenity's wholesale acquisition cost (WAC) is approximately $1,825 per monthly dose, or roughly $21,900 for the full 12-month course. Out-of-pocket costs vary widely depending on insurance.

Medicare Part B: Evenity administered in a provider's office is covered under Medicare Part B as a medical benefit. Patients pay 20% coinsurance after meeting their Part B deductible, which can mean $300 to $400 per injection without supplemental coverage. Medigap plans or Medicare Advantage plans may reduce this.

Commercial insurance: Copays range from $0 to $150 per injection for patients with specialty tier coverage, though some plans place Evenity on a higher cost-sharing tier. Amgen offers the Evenity copay card program for commercially insured patients, which may reduce copays to as low as $5 per month for eligible patients.

MassHealth (Medicaid): Patients approved through prior authorization typically pay minimal or no copay.

Uninsured or underinsured patients: The Amgen Safety Net Foundation provides Evenity at no cost to qualifying patients. Eligibility is generally based on household income at or below 400% of the federal poverty level and lack of prescription drug coverage.

Massachusetts patients should also check with the state's Health Connector marketplace plans during open enrollment. Plans purchased through the Connector must comply with the state's essential health benefits requirements, which include coverage for specialty pharmaceuticals with appropriate utilization management.

Monitoring During and After Treatment

During the 12-month romosozumab course, standard monitoring includes:

• Serum calcium checked at 2 to 4 weeks after the first injection and periodically thereafter to monitor for hypocalcemia
• Bone turnover markers (P1NP and CTX) at baseline, 3 months, and 12 months. P1NP typically peaks at month 1 and returns toward baseline by month 9. CTX decreases progressively.
• DXA scan at 12 months to quantify BMD response. Expected gains: 11 to 15% at the lumbar spine and 3 to 5% at the total hip based on FRAME trial data [3].
• Cardiovascular symptom review at each monthly injection visit, per the black box warning requirements. New chest pain, neurological symptoms, or dyspnea should prompt immediate evaluation.

After transitioning to antiresorptive therapy, DXA monitoring continues per ISCD guidelines at 1 to 2 year intervals. The goal is to confirm that the BMD gains from romosozumab are being maintained.

Patients receiving romosozumab should take calcium 1,000 to 1,200 mg daily (from diet plus supplements) and vitamin D 1,000 to 4,000 IU daily throughout treatment. Adequate calcium and vitamin D intake reduces the risk of treatment-associated hypocalcemia and supports optimal bone mineralization.